|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 555 11th STREET, NW |
Address2 | Suite #300 |
City | WASHINGTON |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 288670-12
|
||||||||
|
6. House ID# 371000000
|
TYPE OF REPORT | 8. Year | 2016 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Siri M. Buller |
Date | 4/20/2017 3:29:20 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Federal budget and appropriations for cancer research and programs, including: federal appropriations for NIH, NCI, CDC, FDA; the Prevention & Public Health Fund, including certain votes on issues relating to NIH and cancer moonshot funding in the context of H.R. 2028, the Continuing and Security Assistance Appropriations Act; and, H.R. 34, the 21st Century Cures Act. Also issues relating to non-communicable diseases with respect to S.3117, the State/Foreign Operations FY17 Appropriations legislation, the House companion draft Appropriations bill, and the Continuing Resolution for FY17 enacted prior to October 1, 2016.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), White House Office, Centers For Disease Control & Prevention (CDC), State - Dept of (DOS), Natl Institutes of Health (NIH), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Matthew |
Phelan |
|
|
|
David |
Pugach |
|
|
|
Gregg |
Haifley |
|
|
|
Richard |
Woodruff |
|
|
|
Keysha |
Brooks-Coley |
|
|
|
Maggie |
Osborne |
|
|
|
Greta |
Johnson |
|
|
|
Katrina |
Kamm |
|
|
|
Lauren |
Coatoam |
|
|
|
Caroline |
Powers |
|
|
|
Rosalie |
Abbott |
|
|
|
Sherry |
McCammon |
|
|
|
Dana |
Bacon |
|
|
|
Rachel |
Marcus |
|
Previously employed by Sen. Blanche L. Lincoln (D-AR) |
|
Emily |
White |
|
|
|
Paul |
Holmes |
|
|
|
Matthew |
Caston |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Issues relating to implementation of legislative or regulatory changes to Medicare and Medicaid, including Medicare Part B drug reimbursement. Issues before CMS relating to Medicare payment for preventive screening, coordinated patient care, care planning; H.R.1220 & S.624, Removing Barriers to Colorectal Cancer Screening Act; and H.R.1190, Protecting Seniors' Access to Medicare Act and issues relating to CMS-issued regulations pertaining to Medicare Part B reimbursement, regulations relating to the Medicare Access and CHIP Reauthorization Act of 2015.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Matthew |
Phelan |
|
|
|
Keysha |
Brooks-Coley |
|
|
|
Gregg |
Haifley |
|
|
|
Richard |
Woodruff |
|
|
|
Katrina |
Kamm |
|
|
|
Caroline |
Powers |
|
|
|
Rosalie |
Abbott |
|
|
|
Sherry |
McCammon |
|
|
|
Dana |
Bacon |
|
|
|
Rachel |
Marcus |
|
Previously employed by Sen. Blanche L. Lincoln (D-AR) |
|
Emily |
White |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TOB
16. Specific lobbying issues
Issues relating to smoking cessation, tobacco sales to minors, tobacco taxes, minimum smoking age, graphic warning labels, product regulation, and smokefree environments, including: implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31), including the proposed FDA deeming regulations. Issues relating to tobacco and trade, including: the Trans-Pacific Partnership and Transatlantic Trade and Investment Partnership; proposed FDA regulation of electronic cigarettes and/or cigars; H.R.478/S.430, Protecting Children from Electronic Cigarette Advertising Act; H.R.3042, Stop Tobacco Sales to Youth Act; S.450, Tobacco Tax Equity Act; H.R.1749, STOP Act; and S.1129, Tobacco Tax and Enforcement Reform Act. Issues related to FDA tobacco control, as considered in House and Senate, FY17 Agriculture Appropriations legislation and Labor, Health and Human Services Appropriations legislation.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), White House Office, U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Richard |
Woodruff |
|
|
|
Gregg |
Haifley |
|
|
|
David |
Pugach |
|
|
|
Katrina |
Kamm |
|
|
|
Keysha |
Brooks-Coley |
|
|
|
Matthew |
Phelan |
|
|
|
Greta |
Johnson |
|
|
|
Caroline |
Powers |
|
|
|
Rosalie |
Abbott |
|
|
|
Sherry |
McCammon |
|
|
|
Dana |
Bacon |
|
|
|
Rachel |
Marcus |
|
Previously employed by Sen. Blanche L. Lincoln (D-AR) |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Issues relating to the tax treatment of nonprofits, including governance of nonprofit organizations.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Richard |
Woodruff |
|
|
|
Gregg |
Haifley |
|
|
|
Caroline |
Powers |
|
|
|
Rosalie |
Abbott |
|
|
|
Rachel |
Marcus |
|
Previously employed by Sen. Blanche L. Lincoln (D-AR) |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Issues relating to health disparities, health care reform, childhood cancer, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, tanning beds, skin cancer, and wellness, including: H.R.3119 & S.2748, the Palliative Care and Hospice Education and Training Act; H.R.716 & S.370, the Breast Density & Mammography Reporting Act; H.R.3381 & S.1883, Childhood Cancer STAR Act; and regulations relating to tanning beds. In addition, regulatory issues before the FDA relating to laboratory developed tests, and any legislation pertaining thereto, suncreens, colorectal cancer screening tests, electronic medical devices, H.R.2739/S.1566 - the Cancer Drug Coverage Parity Act, H.R.2846 - Planning Actively for Cancer Treatment Act, S.1014 - Personal Care Products Safety Act, H.R.1608 - Lymphedema Treatment Act, H.R.2191/S.1170 - the Breast Cancer Research Stamp Reauthorization Act, S.705 - Transportation Alternatives Act, S.540 - School Food Modernization Act, and H.R.644 - America Gives More Act, CDC opioid prescription guidelines, and legislation relating to opioid prescribing, addition and rehabilitation; H.R.5475, the Health Equity and Accountability Act; S.2787, the SAME Act and Senate Amendment 4369 to S.2943, the Senate Defense Authorization bill; and S.3136, H.R.5003 childhood nutrition bill; and H.R.2017 and S.2217, the Common Sense Nutrition Disclosure Act; and S.524 and H.R.953, the Comprehensive Addiction and Recovery Act, and related bills and amendments, S.3077, the Marijuana Effective Drug Studies Act of 2016.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Disease Control & Prevention (CDC), Health & Human Services - Dept of (HHS), Labor - Dept of (DOL), White House Office, Food & Drug Administration (FDA), State - Dept of (DOS), Natl Institutes of Health (NIH), U.S. Agency for International Development (USAID), Environmental Protection Agency (EPA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Keysha |
Brooks-Coley |
|
|
|
David |
Pugach |
|
|
|
Matthew |
Phelan |
|
|
|
Richard |
Woodruff |
|
|
|
Gregg |
Haifley |
|
|
|
Maggie |
Osborne |
|
|
|
Greta |
Johnson |
|
|
|
Katrina |
Kamm |
|
|
|
Lauren |
Coatoam |
|
|
|
Caroline |
Powers |
|
|
|
Rosalie |
Abbott |
|
|
|
Sherry |
McCammon |
|
|
|
Rachel |
Marcus |
|
Previously employed by Sen. Blanche L. Lincoln (D-AR) |
|
Emily |
White |
|
|
|
Matthew |
Caston |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |